Drilldown: Medicines

Ondansetron (1)

Zofran, Zofran ODT (1)

[[:Category:5-HT3_antagonists|5-HT3 receptor antagonist]] (1) · [[:Category:Antiemetics|Antiemetic]] (1)

None (1)

'"`UNIQ--vote-00000374-QINU`"', '"`UNIQ--vote-00000375-QINU`"', '"`UNIQ--vote-00000376-QINU`"', '"`UNIQ--vote-00000377-QINU`"' (1)

None · ~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose · '''5 mg PO at bedtime for women, 5-10 mg for men''' (per FDA's 2013 sex-specific dose reduction for women due to slower clearance). Ambien CR 6.25 mg women / 6.25-12.5 mg men. Intermezzo SL 1.75 mg women / 3.5 mg men · 0.25 mg · 0.4 mg PO daily (general prevention); 0.8-1 mg/d in pregnancy; 4 mg/d for women with prior NTD-affected pregnancy; 1 mg/d during methotrexate therapy · 0.4 mg PO once daily, 30 minutes after the same meal each day · 0.5 mg PO once daily · 0.5-1 mg PO/IV once or twice daily; titrate to clinical response. Approximate equipotency: bumetanide 1 mg ≈ furosemide 40 mg ≈ torsemide 20 mg · 0.5-2 mg/kg/d divided or single morning dose for acute conditions; lowest effective dose for chronic conditions, with planned taper · 0.5-3 mg PO 30-60 minutes before bedtime. Some patients respond to micro-doses (0.3 mg) without additional benefit at higher doses. For circadian phase shifting, timing relative to dim-light melatonin onset matters more than absolute dose · 0.5–1 oz (10–30 g) ground for psychoactive effect; far smaller for culinary use · 0.75 mg SC weekly'"`UNIQ--ref-00000053-QINU`"' · 1 capsule (20/10 mg dextromethorphan/quinidine) PO once daily × 7 days, then 1 capsule BID · 1 drop in affected eye(s) TID (monotherapy); BID with timolol (Cosopt) · 1 drop in the affected eye(s) once daily in the evening · 1 drop in the affected eye(s) once daily in the evening (Lumigan); Latisse applied to upper lash line at bedtime · 1 g PO QID on an empty stomach (1 hour before meals and at bedtime); 1 g BID for maintenance · 1 mg at bedtime (PTSD nightmares); 1 mg BID–TID (HTN) · 1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg · 1 mg PO once daily

Other values:

Search

4 mg, 8 mg, 24 mg tablets; 4 mg, 8 mg orally disintegrating tablets; 4 mg/5 mL oral solution; IV (2 mg/mL) (1)

Single doses ≤16 mg (FDA 2012 advisory withdrew the 32 mg single IV dose for QT-prolongation risk); 24-32 mg/d divided (1)

None · Oral · IV · topical · IM · intranasal · rectal · subcutaneous · Topical ophthalmic · ophthalmic · intramuscular · intravenous · transdermal · vaginal · Subcutaneous (abdomen · sublingual · thigh · Inhaled · intra-articular · nebulized

Other values:

Search

30 minutes PO; minutes IV (1)

4-12 hours (1)

3-6 hours (longer in hepatic impairment)'"`UNIQ--ref-00000378-QINU`"' (1)

~60% (oral)'"`UNIQ--ref-00000379-QINU`"' (1)

None (1)

[[USLegal:Prescription only|Rx-only]] in US (1)